Core Insights - Novo Nordisk plans to sell its weight-loss drug Wegovy on the Hims & Hers Health platform, ending a legal dispute between the two companies [1] Company Developments - Novo Nordisk and Hims & Hers Health are expected to announce a new partnership soon, potentially as early as Monday [1] - The resolution of the dispute allows both companies to collaborate on the distribution of obesity drugs, which may enhance market reach and sales [1]

Core Insights - The WHO Foundation has announced a collaboration with Eli Lilly and Company to strengthen health systems for obesity prevention and care, addressing a critical global health challenge [1] - Lilly has committed $1.68 million to the WHO Foundation until 2029 to support these health system strengthening efforts [1] - The initiative aims to improve access to early diagnosis, counseling, and care, reduce the global economic impact of obesity, and mitigate health risks associated with it [1] Health Statistics - In 2022, over 2.5 billion adults and more than 390 million children and adolescents worldwide were overweight, with 1 in 8 people living with obesity [1] - The prevalence of obesity among adults has more than doubled since 1990, while obesity among adolescents has quadrupled [1] - In 2022, 43% of adults aged 18 and older were overweight, and 16% were classified as obese [1] Economic Impact - The economic impact of overweight and obesity is projected to exceed $4 trillion by 2035 [1] - The collaboration aims to help countries assess deficiencies in care and strengthen primary health care systems, particularly in resource-limited settings [1]

Core Viewpoint - AIM ImmunoTech Inc. has successfully closed its rights offering, raising approximately $1.8 million to support the development of its lead product, Ampligen® (rintatolimod), aimed at treating late-stage pancreatic cancer, a significant global health issue [1][5]. Group 1: Rights Offering Details - The rights offering allowed holders to purchase one unit at a subscription price of $1,000, which included one share of Series G Convertible Preferred Stock and 2,000 Class G Common Stock Purchase Warrants [2]. - Maxim Group LLC served as the dealer-manager for the rights offering [2]. Group 2: Regulatory Information - The registration statement for the rights offering was declared effective by the SEC on February 10, 2026, with modifications made in a prospectus supplement filed on February 27, 2026 [3]. - The prospectus detailing the terms of the rights offering is available on the SEC's website [3]. Group 3: Company Overview - AIM ImmunoTech Inc. focuses on the research and development of Ampligen®, which is a dsRNA and selective TLR3 agonist immuno-modulator showing broad-spectrum activity in clinical trials for late-stage pancreatic cancer [5].

Core Viewpoint - Lisata Therapeutics, Inc. has entered into a definitive agreement to be acquired by Kuva Labs Inc., with stockholders set to receive $5.00 per share in cash plus a contingent value right for an additional $1.00 per share, contingent on regulatory milestones [2][3][4]. Transaction Details - The merger agreement stipulates that Kuva will initiate a tender offer to acquire all outstanding shares of Lisata for $5.00 per share in cash, along with one contingent value right (CVR) per share [3]. - The CVR allows holders to receive an additional $1.00 per share if a New Drug Application for the product candidate certepetide is filed or accepted by the FDA within a specified timeframe [3]. - The transaction is expected to close in the second quarter of 2026, subject to customary offer conditions, including the tender of a majority of Lisata's outstanding shares [4]. Board of Directors Recommendation - The board of directors of Lisata has unanimously approved the merger agreement, determining it to be fair and in the best interests of the stockholders, and recommends that all stockholders accept the offer [6]. Post-Transaction Status - Upon completion of the transaction, Lisata will become part of Kuva, its common stock will be delisted from Nasdaq, and it will apply to deregister its common stock, ceasing to be a reporting company under U.S. securities laws [5]. Company Background - Lisata Therapeutics is a clinical-stage pharmaceutical company focused on developing innovative therapies for advanced solid tumors and other serious diseases, with its product candidate certepetide designed to enhance the targeting of anti-cancer drugs [8]. - Kuva Labs is a preclinical bioscience company developing a proprietary imaging platform aimed at improving cancer diagnosis and treatment [10].

New York, New York--(Newsfile Corp. - March 6, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) between October 31, 2024 and December 30, 2025, inclusive (the "Class Period"), of the important April 21, 2026 lead plaintiff deadline.SO WHAT: If you purchased Corcept common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingen ...

Vancouver, British Columbia--(Newsfile Corp. - March 6, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of disease-modifying small molecule drug candidates that target CB1/CB2 receptors, today announced an update regarding BayMedica LLC ("BayMedica"), a wholly owned subsidiary of the Company, in light of ongoing uncertainty surrounding U.S. federal legislation.As previously announced, H.R. 5371, the "Continuing Appropria ...

PresentationJason Awe All right. Good morning, everyone, and thank you for joining us for AtaiBeckley's 2026 Investor Day. Before we begin, I'd like to remind everyone that this call and presentation will contain forward-looking statements. These statements are subject to risks and uncertainties, and actual results may differ materially. We undertake no obligation to update our forward-looking statements, except as required by law. Additional information can be found in our SEC filings. With that, let's rev ...

PresentationRitu BaralTD Cowen, Research Division Thank you, everyone, for joining us for the Praxis fireside chat here at the TD Cowen Healthcare Conference. I'm covering analyst Ritu Baral, and joining us from Praxis, We have Marc -- come back, Marcio. We have, to my right, Tim Kelly, CFO, and Marcio De'Souza, CEO, who I'm sure you guys all know. Let's start right away. I know right. Well, thank you guys for doing the breakfast this morning. We were really able to get into some of the nitty gritty, and w ...

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces the European Commission Approval of Zynyz (retifanlimab) for First-Line Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC). ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...